NCT06082050View on ClinicalTrials.gov

Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 2, 2023

Primary Completion Date

July 3, 2025

Study Completion Date

February 10, 2026

Conditions
Transthyroxin Amyloidosis Cardiomyopathy
Interventions
DRUG

YOLT-201

Infusion of YOLT-201 at Day 1， Subjects may voluntarily accept the second study drug treatment at the OBD (Optimal Biological Dose) level.

Trial Locations (1)

310009

RECRUITING

the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

YolTech Therapeutics Co., Ltd

INDUSTRY

lead

Zhejiang University

OTHER